INFI - Infinity Pharmaceuticals added to the NASDAQ Biotechnology Index

Infinity Pharmaceuticals (NASDAQ:INFI) trades 1.3% down premarket has been selected for addition to the NASDAQ Biotechnology Index, effective Dec.20 as of market open. To be selected for addition to the index, a company must have a minimum market capitalization of $200M demonstrate an average daily trading volume of at least 100K shares and must be Nasdaq-listed. The index is modified market capitalization-weighted such that constituents are capped at 8% (for the top 5) and at 4% (for the remaining) at each quarterly index rebalance; the entire index is reviewed and reconstituted annually in December. "Our eganelisib data have continued to mature in very positive ways with presentations at SABCS and ASCO GU this year, demonstrating clinically meaningful outcomes in both metastatic triple negative breast cancer and urothelial cancer, respectively." CEO and chair Adelene Perkins commented.

For further details see:

Infinity Pharmaceuticals added to the NASDAQ Biotechnology Index